goetzpartners securities Limited

Vivoryon Therapeutics (PBD-NA): Agreement with MOR in I-O, earlier than expected

Abivax SA (ABVX-FR): Ready to deal with inflammation

Mauna Kea Technologies SA (MKEA-FR): Reimbursement decision facilitates Cellvizio penetration in France

Vivoryon Therapeutics (PBD-NA): Fresh funding for AD. Immuno-oncology optionality explored

Marinomed Biotech AG: Q1 masks solid sales performance in most markets

Evotec SE (EVT-DE): Evotec expands into high-growth biologics segment

Vicore Pharma Holding AB (VICO-SE): Key activities on track at Q1/2019 update

Advanced Oncotherapy (AVO-GB): Strong fundamentals underpin future growth

Epigenomics (ECX-DE): Key catalysts to fuel growth throughout 2019

Evotec SE (EVT-DE): Macro trend drives strong start to the year

Marinomed Biotech AG (MARI-AT): Budesolv hits key endpoints in Phase III allergy trial

Evotec SE (EVT-DE): Q1 results beat on strong top-line growth

Evotec SE (EVT-DE): Q1/2019E results preview

Marinomed Biotech AG (MARI-AT): 2019E off to a good start. All eyes on Budesolv.

Curetis (CURE-NL): Partnering drives turn-round

Mauna Kea Technologies SA (MKEA-FR): Progressing toward long-term strategic growth

Vicore Pharma Holding AB (VICO-SE): Scleroderma the second indication for VP01 (C21)

Marinomed Biotech AG (MARI-AT): Budesolv succeeds in pivotal Phase III trial

Immutep Limited (IMM-AU): Unlocking the value of LAG-3 in autoimmunity

Basilea Pharmaceutica AG (BSLN-CH): Derazantinib has potential in iCCA and beyond

Advanced Oncotherapy (AVO-GB): Key talent acquisition reaffirms the promise of LIGHT

Mauna Kea Technologies SA (MKEA-FR): FY2018 results validate move to consignment sales

Evotec SE (EVT-DE): Raising TP to EUR28 on positive momentum

Epigenomics (ECX-DE): 2018 results highlight strong underlying growth momentum

Vicore Pharma Holding AB (VICO-SE): Pipeline on track at FY2018. Moving to IFRS

Marinomed Biotech AG (MARI-AT): Solving the insoluble

Probiodrug (PBD-NA): $15m cash injection from NIH for US Phase IIb in early Alzheimer’s

Telix Pharmaceuticals Limited (TLX-AU): Updated PCa imaging guidelines de-risk lead asset

Nexstim OYJ (NXTMH-FI): FY2018 results reflect growing focus on therapy

Abivax SA (ABVX-FR): ABX464: sustained safety and benefit in inflammatory bowel